rademikibart
·Code: CBP-201
rademikibart: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Connect Biopharma Holdings Ltd (CNTB) | Phase 2 |
FDA Decisions
FDA_MeetingFDA provided written agreement on the final study protocol, enabling initiation of the Phase 2 Seabreeze STAT COPD study of rademikibart.(CNTB)
Frequently asked questions
Who is developing rademikibart?
rademikibart is being developed by Connect Biopharma Holdings Ltd.
What is rademikibart's latest FDA decision?
The most recent tracked FDA decision for rademikibart is FDA_Meeting for FDA provided written agreement on the final study protocol, enabling initiation of the Phase 2 Seabreeze STAT COPD study of rademikibart., dated May 14, 2025.
Get deeper analysis on rademikibart
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis